Akari Therapeutics, Plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 2836 www.akaritx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics, Plc

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading - Jun 9th, 2026 9:11 am
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week - Jun 5th, 2026 9:06 am
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Jun 4th, 2026 9:08 am
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026 - Jun 4th, 2026 7:30 am
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Jun 2nd, 2026 9:08 am
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading - Jun 1st, 2026 9:11 am
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance - May 28th, 2026 4:33 pm
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday - May 28th, 2026 9:14 am
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance - May 28th, 2026 7:17 am
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - May 27th, 2026 9:08 am
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading - May 22nd, 2026 9:06 am
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models - May 21st, 2026 3:01 pm
European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading - May 21st, 2026 9:05 am
Akari Therapeutics Announces $5.5 Million Private Placement Offering - May 21st, 2026 6:30 am
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - May 19th, 2026 9:27 am
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase - May 18th, 2026 7:05 am
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading - May 14th, 2026 9:05 am
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - May 13th, 2026 9:12 am
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading - May 12th, 2026 9:14 am
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets - May 12th, 2026 6:33 am